Prevalence of multidrug-resistant bacteria at a tertiary-care teaching hospital in Mexico: Special focus on Acinetobacter baumannii

Chemotherapy

Volumn 56, Issue 4, 2010, Pages 275-279

  Garza González, Elvira ^a   Llaca Díaz, Jorge Martín ^b   Bosques Padilla, Francisco Javier ^b   González, Gloria M ^a  

^a Medicina UANL   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Acinetobacter baumannii; Meropenem; Multidrug resistance

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT; MEXICO; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS AUREUS; TEACHING HOSPITAL; TERTIARY HEALTH CARE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; HOSPITALS, TEACHING; HUMANS; KLEBSIELLA PNEUMONIAE; MEXICO; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; STAPHYLOCOCCUS AUREUS; THIENAMYCINS;

EID: 77955212832     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000319903     Document Type: Article

References (23)

1. Gould I: The epidemiology of antibiotic resistance. Int J Antimicrob Agents 2008; 32(Suppl 1):S2-S9.
2. Lowy F: Staphylococcus aureus infections. N Engl J Med 1998; 339: 520-532.
3. Slama T: Gram-negative antibiotic resistance: there is a price to pay. Crit Care 2008; 12(Suppl 4):S4.
4. Hawkey P: The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008; 62(Suppl 1):i1-i9.
5. Peleg A, Seifert H, Paterson D: Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008; 21: 538-582.
6. Munoz-Price L, Weinstein R: Acinetobacter infection. N Engl J Med 2008; 358: 1271-1281.
7. Perez F, Hujer A, Hujer K, Decker B, Rather P, Bonomo R: Global challenge of multidrugresistant Acinetobacter baumannii . Antimicrob Agents Chemother 2007; 51: 3471-3484.
8. Rhomberg P, Jones R, Sader H, Fritsche T: Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003). Diagn Microbiol Infect Dis 2004; 49: 273-281.
9. Stamm W, Grayson ML, Nicolle L, Powell M: WHO global strategy for containment of antimicrobial resistance (document No: WHO/ cds/csr/drs/2001.2). Geneva, World Health Organization, 2001.
10. Institute CaLS: Performance Standards for Antimicrobial Susceptibility Testing, 19th informational supplement document m100-s19. Wayne, Clinical and Laboratory Standards Institute, 2009.
11. BSAC standardized disc susceptibility testing method; in: BSAC Methods for Antimicrobial Susceptibility Testing, Version 7. 2008. http://www.bsac.org. uk/-db/-documents/version-7.pdf.
12. Chemotherapy: BSAC standardized disc susceptibility testing method. BSAC Methods for Antimicrobial Susceptibility Testing, Version 7. 2008. http://www.bsac.org.uk/-db/-documents/version-7.pdf.
13. Ramphal R: Importance of adequate initial antimicrobial therapy. Chemotherapy 2005; 51: 171-176.
14. Al-Tawfiq J, Mohandhas T: Prevalence of antimicrobial resistance in Acinetobacter calcoaceticus- baumannii complex in a Saudi Arabian hospital. Infect Control Hosp Epidemiol 2007; 28: 870-872.
15. Gales A, Jones R, Forward K, Liñares J, Sader H, Verhoef J: Emerging importance of multidrug- resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the sentry antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001; 32(Suppl 2):S104-S113.
16. Seifert H, Dowzicky M: A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the tigecycline evaluation and surveillance trial (2004-2007). Chemotherapy 2009; 55: 241-252.
17. Reinert R, Low D, Rossi F, Zhang X, Wattal C, Dowzicky M: Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of test and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60: 1018-1029.
18. Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C: Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Chemotherapy 2009; 55: 20-27.
19. Cornejo-Juárez P, Velásquez-Acosta C, Díaz- González A, Volkow-Fernández P: Trend of antimicrobial drug-susceptibility of blood isolates at an oncological center (1998-2003) (in Spanish). Salud Publica Mex 2005; 47: 288-293.
20. Guajardo-Lara C, González-Martínez P, Ayala-Gaytán J: Antibiotic resistance of Escherichia coli from community-acquired urinary tract infections. What antimicrobial to use (in Spanish)? Salud Publica Mex 2009; 51: 155-159.
21. Rodríguez J, Ethlvarez J, Escribano I, Royo G: In vitro activity of linezolid against Staphylococcus aureus: a population study. Chemotherapy 2005; 51: 86-88.
22. Livermore D: Linezolid in vitro: Mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51(suppl 2):ii9-ii16.
23. Mutnick A, Biedenbach D, Turnidge J, Jones R: Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the Sentry Antimicrobial Surveillance Program, 1998-2000. Diagn Microbiol Infect Dis 2002; 43: 65-73.